Latest filings (excl ownership)
8-K
Regulation FD Disclosure
29 Apr 24
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEF 14A
Definitive proxy
29 Mar 24
PRE 14A
Preliminary proxy
20 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
S-8
Registration of securities for employees
16 Feb 24
8-K
Other Events
11 Jan 24
8-K
Other Events
11 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 Nov 23
424B5
Prospectus supplement for primary offering
29 Sep 23
8-K
Capricor Therapeutics Announces $23 Million Registered Direct Offering
29 Sep 23
FWP
Free writing prospectus
29 Sep 23
8-K
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
29 Sep 23
8-K
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
6 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7 Aug 23
8-K
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
24 Jul 23
8-K
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
13 Jul 23
8-K/A
Amendments to Articles of Incorporation or Bylaws
15 Jun 23
8-K/A
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
13 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
11 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEF 14A
Definitive proxy
17 Apr 23
PRE 14A
Preliminary proxy
7 Apr 23
10-K
2022 FY
Annual report
17 Mar 23
8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
15 Mar 23
8-K
Entry into a Material Definitive Agreement
16 Feb 23
S-8
Registration of securities for employees
30 Jan 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Capricor Therapeutics Reports Third Quarter 2022 Financial
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Capricor Therapeutics Reports Second Quarter 2022 Financial
10 Aug 22
8-K
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of
19 Jul 22
8-K
Regulation FD Disclosure
29 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 22
Latest ownership filings
4
EARL M COLLIER JR
25 Apr 24
4
David B Musket
24 Apr 24
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7 Feb 24
4
Mike Kelliher
4 Jan 24
4
Philip J Gotwals
4 Jan 24
4
Paul Gisbert Auwaerter
4 Jan 24
4
David B Musket
4 Jan 24
4
GEORGE W DUNBAR JR
4 Jan 24
4
Karimah Es Sabar
4 Jan 24
4
EARL M COLLIER JR
4 Jan 24
4
Frank Litvack
4 Jan 24
4
Linda Marban
4 Jan 24
4
Karen Krasney
4 Jan 24
4
Anthony Bergmann
4 Jan 24
4
Anthony Bergmann
24 Oct 23
SC 13G
Nippon Shinyaku Co Ltd
17 Oct 23
4
David B Musket
13 Oct 23
4
EARL M COLLIER JR
12 Oct 23
4
David B Musket
11 Oct 23
4
Paul Gisbert Auwaerter
10 Oct 23
4
David B Musket
6 Oct 23
4
Mike Kelliher
6 Sep 23
3
Mike Kelliher
6 Sep 23
4
Frank Litvack
16 Aug 23
4
Philip J Gotwals
24 Jul 23
3
Philip J Gotwals
24 Jul 23
4
Paul Gisbert Auwaerter
13 Jul 23
3
Paul Gisbert Auwaerter
13 Jul 23
4
Linda Marban
16 May 23
4
Xavier Avat
27 Apr 23
4
Xavier Avat
7 Apr 23
4
Louis Manzo
23 Feb 23
4
Frank Litvack
23 Feb 23
4
GEORGE W DUNBAR JR
15 Feb 23
4
EARL M COLLIER JR
15 Feb 23
4/A
Karimah Es Sabar
6 Jan 23
4
Karimah Es Sabar
5 Jan 23
4
David B Musket
5 Jan 23
4
Louis Manzo
5 Jan 23
4
GEORGE W DUNBAR JR
5 Jan 23